The decreased susceptibility of Bcr/Abl targets to NK cell-mediated lysis in response to imatinib mesylate involves modulation of NKG2D ligands, GM1 expression, and synapse formation - PubMed (original) (raw)
. 2006 Jan 15;176(2):864-72.
doi: 10.4049/jimmunol.176.2.864.
Affiliations
- PMID: 16393970
- DOI: 10.4049/jimmunol.176.2.864
Free article
The decreased susceptibility of Bcr/Abl targets to NK cell-mediated lysis in response to imatinib mesylate involves modulation of NKG2D ligands, GM1 expression, and synapse formation
Christelle Cebo et al. J Immunol. 2006.
Free article
Abstract
Chronic myeloid leukemia is a clonal multilineage myeloproliferative disease of stem cell origin characterized by the presence of the Bcr/Abl oncoprotein, a constitutively active tyrosine kinase. In previous studies, we have provided evidence that Bcr/Abl overexpression in leukemic cells increased their susceptibility to NK-mediated lysis by different mechanisms. In the present study, using UT-7/9 cells, a high level Bcr/Abl transfectant of UT-7 cells, we show that the treatment of Bcr/Abl target by imatinib mesylate (IM), a specific Abl tyrosine kinase inhibitor, hampers the formation of the NK/target immunological synapse. The main effect of IM involves an induction of surface GM1 ganglioside on Bcr/Abl transfectants that prevents the redistribution of MHC-related Ag molecules in lipid rafts upon interaction with NK cells. IM also affects cell surface glycosylation of targets, as assessed by binding of specific lectins resulting in the subsequent modulation of their binding to lectin type NK receptor, particularly NKG2D. In addition, we demonstrate that the tyrosine kinase activity repression results in a decrease of MHC-related Ags-A/B and UL-16-binding protein expression on Bcr/Abl transfectants UT-7/9. We show that NKG2D controls the NK-mediated lysis of UT-7/9 cells, and IM treatment inhibits this activating pathway. Taken together, our results show that the high expression of Bcr/Abl in leukemic cells controls the expression of NKG2D receptor ligands and membrane GM1 via a tyrosine kinase-dependent mechanism and that the modulation of these molecules by IM interferes with NK cell recognition and cytolysis of the transfectants.
Similar articles
- BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia.
Boissel N, Rea D, Tieng V, Dulphy N, Brun M, Cayuela JM, Rousselot P, Tamouza R, Le Bouteiller P, Mahon FX, Steinle A, Charron D, Dombret H, Toubert A. Boissel N, et al. J Immunol. 2006 Apr 15;176(8):5108-16. doi: 10.4049/jimmunol.176.8.5108. J Immunol. 2006. PMID: 16585609 - Altered IFNgamma signaling and preserved susceptibility to activated natural killer cell-mediated lysis of BCR/ABL targets.
Cebo C, Voutsadakis IA, Da Rocha S, Bourhis JH, Jalil A, Azzarone B, Turhan AG, Chelbi-Alix M, Chouaib S, Caignard A. Cebo C, et al. Cancer Res. 2005 Apr 1;65(7):2914-20. doi: 10.1158/0008-5472.CAN-04-1932. Cancer Res. 2005. PMID: 15805294 - The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity.
Salih J, Hilpert J, Placke T, Grünebach F, Steinle A, Salih HR, Krusch M. Salih J, et al. Int J Cancer. 2010 Nov 1;127(9):2119-28. doi: 10.1002/ijc.25233. Int J Cancer. 2010. PMID: 20143399 - Rho-signaling pathways in chronic myelogenous leukemia.
Kuzelová K, Hrkal Z. Kuzelová K, et al. Cardiovasc Hematol Disord Drug Targets. 2008 Dec;8(4):261-7. doi: 10.2174/187152908786786241. Cardiovasc Hematol Disord Drug Targets. 2008. PMID: 19075636 Review. - Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders.
Pardanani A, Tefferi A. Pardanani A, et al. Blood. 2004 Oct 1;104(7):1931-9. doi: 10.1182/blood-2004-01-0246. Epub 2004 May 27. Blood. 2004. PMID: 15166033 Review.
Cited by
- Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells.
Carlsten M, Järås M. Carlsten M, et al. Front Immunol. 2019 Oct 11;10:2357. doi: 10.3389/fimmu.2019.02357. eCollection 2019. Front Immunol. 2019. PMID: 31681270 Free PMC article. Review. - Molecular Bases for the Regulation of NKG2D Ligands in Cancer.
Huergo-Zapico L, Acebes-Huerta A, López-Soto A, Villa-Álvarez M, Gonzalez-Rodriguez AP, Gonzalez S. Huergo-Zapico L, et al. Front Immunol. 2014 Mar 21;5:106. doi: 10.3389/fimmu.2014.00106. eCollection 2014. Front Immunol. 2014. PMID: 24711808 Free PMC article. Review. - Targeted Therapies: Friends or Foes for Patient's NK Cell-Mediated Tumor Immune-Surveillance?
Damele L, Ottonello S, Mingari MC, Pietra G, Vitale C. Damele L, et al. Cancers (Basel). 2020 Mar 25;12(4):774. doi: 10.3390/cancers12040774. Cancers (Basel). 2020. PMID: 32218226 Free PMC article. Review. - Manipulating the NKG2D Receptor-Ligand Axis Using CRISPR: Novel Technologies for Improved Host Immunity.
Alves E, McLeish E, Blancafort P, Coudert JD, Gaudieri S. Alves E, et al. Front Immunol. 2021 Aug 12;12:712722. doi: 10.3389/fimmu.2021.712722. eCollection 2021. Front Immunol. 2021. PMID: 34456921 Free PMC article. - Novel immune modulators used in hematology: impact on NK cells.
Krieg S, Ullrich E. Krieg S, et al. Front Immunol. 2013 Jan 3;3:388. doi: 10.3389/fimmu.2012.00388. eCollection 2012. Front Immunol. 2013. PMID: 23316191 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous